Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of liraglutide on body weight in overweight or obese subjects with type 2 diabetes
2008-002199-88Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM), obesity and Overweight comparing Liraglutide with Placebo (2 arms). Primary endpoint: Change from baseline in body weight at 56 weeks. Started Sep 2008; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesityOverweight
Beyond the preview
Go deeper on 2008-002199-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002199-88.